These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 19170595

  • 1. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
    Powley MW, Frederick CB, Sistare FD, DeGeorge JJ.
    Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
    [Abstract] [Full Text] [Related]

  • 2. Metabolites in safety testing.
    Robison TW, Jacobs A.
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [Abstract] [Full Text] [Related]

  • 3. Strategy for genotoxicity testing--metabolic considerations.
    Ku WW, Bigger A, Brambilla G, Glatt H, Gocke E, Guzzie PJ, Hakura A, Honma M, Martus HJ, Obach RS, Roberts S, Strategy Expert Group, IWGT.
    Mutat Res; 2007 Feb 03; 627(1):59-77. PubMed ID: 17141553
    [Abstract] [Full Text] [Related]

  • 4. Introduction: Human metabolites in safety testing (MIST) issue.
    Guengerich FP.
    Chem Res Toxicol; 2009 Feb 03; 22(2):237-8. PubMed ID: 19216576
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
    Gómez-Lechón MJ, Castell JV, Donato MT.
    Chem Biol Interact; 2007 May 20; 168(1):30-50. PubMed ID: 17134688
    [Abstract] [Full Text] [Related]

  • 13. Implications of the allosteric kinetics of cytochrome P450s.
    Atkins WM.
    Drug Discov Today; 2004 Jun 01; 9(11):478-84. PubMed ID: 15149623
    [Abstract] [Full Text] [Related]

  • 14. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
    Walker D, Brady J, Dalvie D, Davis J, Dowty M, Duncan JN, Nedderman A, Obach RS, Wright P.
    Chem Res Toxicol; 2009 Oct 01; 22(10):1653-62. PubMed ID: 19715349
    [Abstract] [Full Text] [Related]

  • 15. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism.
    Muruganandan S, Sinal CJ.
    Clin Pharmacol Ther; 2008 Jun 01; 83(6):818-28. PubMed ID: 18388875
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
    Zhu M, Zhang D, Zhang H, Shyu WC.
    Biopharm Drug Dispos; 2009 May 01; 30(4):163-84. PubMed ID: 19544287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.